2025 International Congress » Parkinson’s Disease: Pharmacology and Medical Management

A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations

Y. Okuma (Izunokuni, Japan)

A novel virtual home-safety fall prevention program for Parkinson’s Disease

M. Afshari, V. Palakuzhy, G. Jones, A. Hernandez, B. Ouyang, C. Goetz (Chicago, USA)

Anti-Parkinsonian effects of Globimetula cupulata leaf extract and its underlying mechanisms in 6-hydroxydopamine-lesioned rat model

A. Hamadjida, R. Ayissi Mbomo, S. Minko, F. Ntchapda, J. Mingoas Kilekoung (BERTOUA, Cameroon)

Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease

JV. Costa, EF. Muricy, FS. Brito, GS. Nunes, SC. Baran, GV. de Vasconcelos, CF. Do Nascimento, NS. Dos Santos, JX. Oliveira, ME. Vassoler, FG. Nascimento, AM. Guerra, RB. Kauark (Salvador, Brazil)

Antiparkinson Medication Reduces the Probability of the Multiple Step Saccade Pattern During a Memory-Guided Saccade Task

M. Munoz, J. Reilly, E. Zou, Y. Rivera, G. Pal, L. Verhagen Metman, L. Goelz, D. Corcos, F. David (Chicago, USA)

Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301

F. Moreira, L. Wojtecki, W. Jost, D. Santos Garcia, J. Kassubek, M. Fonseca, H. Brigas, G. Harrison-Jones, I. Pijuan (Duesseldorf, Germany)

Botulinium toxin in treatment of Parkinsonism

A. Wankar (Nagpur, India)

Carvacrol modulates rotenone-induced Nigrostriatal Neuronal Death and Angiogenesis via targeting AMPK/FOXO3 transcription factor O3 Signaling cascade

D. Singh (Allahabad, India)

Chronic kidney disease, proteinuria, and mortality risk in patients with Parkinson’s disease: A longitudinal study

K. Baik, M. Park, M. Kang, YJ. Park, SJ. Chung, K. Oh, SH. Kang, S. Koh (Seoul, Republic of Korea)

Clinical Picture of Acute Akinetic Collapse Leading to Multi-Day Immobility in Parkinson’s Disease

S. Kobayashi, Y. Hagihara, M. Inoue, J. Nakamura, T. Chiba, K. Hokkoku (Tokyo, Japan)

Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study

M. Barrett, R. Heo, N. Mukhopadhyay (Richmond, USA)

Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

Comparative Analysis of miR-29a Expression in Optimized Medical Therapy and Intestinal Infusion Therapies in Advanced Parkinson’s Disease

I. Straka, S. Valaskova, Z. Andre, M. Minar, J. Kyselovic, A. Gazova (Bratislava, Slovakia)

Comparative Efficacy and Safety of Opicapone in Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis

A. Abunamoos, Y. Aljazi, F. Qtaishat, A. Rababah, M. Mustafa, F. Alnajjar, M. Alghaniem (Amman, Jordan)

Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis

A. Al Midani, A. Ahmad, O. Razouk, L. Mohamedali, M. Al Khalidi, B. Al Karam, A. Khater (Sharjah, United Arab Emirates)

Comparing the Impact of Levodopa versus Pramipexole on Eye-Tracking Parameters in Treatment-Naïve Parkinson’s Disease: A Longitudinal Study

Z. Kosutzka, L. Hapakova, I. Straka, A. Kusnirova, M. Minar (Bratislava, Slovakia)

COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Six Months Analysis Of REONPARK Study

L. López-Manzanares, M. Cerdán Sánchez, B. Solano Vila, J. García-Caldentey, A. Rodríguez-Sanz, J. Olivares Romero, H. Brigas, D. Martins, J. Blanco Ameijeiras, M. Rodríguez-de Miguel (Madrid, Spain)

COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Three Months Analysis Of REONPARK Study

L. López-Manzanares, M. Cerdán Sánchez, T. Delgado Ballestero, B. Solano Vila, J. García-Caldentey, A. Rodríguez-Sanz, H. Brigas, D. Martins, J. Blanco Ameijeiras, M. Rodríguez-de Miguel (Madrid, Spain)

Continuous Subcutaneous Dopaminergic Stimulation: Exploring the impact of Foslevodopa/Foscarbidopa on Gait in Parkinson’s disease.

C. O'Keeffe, J. Inocentes, M. Bradley, A. Gallagher, F. Ruggieri, R. Walsh, T. Lynch, R. Reilly, C. Fearon (Dublin, Ireland)

Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease

A. Johansson, E. Pekkonen, L. Dorresteijn, P. Schwingenschuh, J. Szász, L. Bergmann, M. O'Meara, J. Parra, M. Südmeyer (Helsinki, Finland)

Dietary Caffeic Acid Exhibits Neuroprotective and Neuromodulatory Effects in a Parkinsonian Rat Model by Mitigating Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis

A. Singh (Prayagraj, India)

Disease Modifying Potential of a Novel ROCK Inhibitor in Rodent Models of Synucleinopathy

M. Kubik, J. Mackeigan, A. Stoll, J. Patterson, J. Lipton, K. Steece-Collier, A. Cole-Strauss, C. Kemp, J. Howe, K. Miller, F. Manfredsson, S. Celano, K. Luk, C. Sortwell (Grand Rapids, USA)

Do Peripheral Inflammatory Markers Predict Impulse Control Disorders in Parkinson’s Disease? Insights from a Retrospective Study

N. Durmaz Celi̇k, M. Yildiz, S. Ozkan (Eskisehir, Turkey)

Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study

K. Kakuda, Y. Kimura, K. Ikenaka, H. Mochizuki (Suita, Japan)

Down-titration of levodopa complicated by catatonia

D. Newbold, . (New York, USA)

Early Introduction of COMT Inhibitors at Low Levodopa Doses Improves Long-Term Motor Complications in Parkinson’s Disease: A sub-analysis of the REONPARK Study

J. García-Caldentey, D. Vilas Roldán, L. López-Manzanares, H. Brigas, D. Martins, J. Reis, J. Blanco Ameijeiras, M. Rodríguez-de Miguel, I. Tegel Ayuela (Palma de Mallorca, Spain)

Effect of Antihypertensive Agent Choice on Parkinson’s Disease Progression in Patients with Hypertension

R. Gologorsky, A. Zolin, H. Ooi, H. Sarva (New York, USA)

Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.

M. Bradley, E. Donlon, A. Gallagher, C. O'Keefe, J. Inocentes, F. Ruggieri, R. Reilly, R. Walsh, T. Lynch, C. Fearon (Dublin, Ireland)

Effect of COVID-19 Pandemic on Utilization of Parkinson’s Medications in Saudi Arabia: A Repeated Cross-Sectional Study

K. Orayj (Abha, Saudi Arabia)

Effectiveness of Opicapone Added to Different Levodopa Doses and LEDDs in Parkinson’s Disease: Post-Hoc Analysis of the ADOPTION Trials

J. Ferreira, JY. Lee, HI. Ma, B. Jeon, W. Poewe, A. Antonini, F. Stocchi, D. Rodrigues, M. Fonseca, H. Brigas, J. Holenz, O. Rascol (Lisbon, Portugal)

Effects of Exogenous Melatonin on Sleep and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-Analysis

M. Alghaniem, A. Abunamoos, F. Qtaishat, A. Rababah, M. Abu Hasna, Y. Aljazi, M. Mustafa, F. Alnajjar, T. Patel, N. Hamam (Amman, 11942, Jordan)

Efficacy And Safety of Fecal Microbiota Transplant for Parkinson’s Disease: A Systematic Review And Meta-Analysis

A. Koppanatham, A. Bin Gulzar, M. Ammar Arshad, E. de Farias, V. Suresh, M. Tariq, R. Vasireddy, T. Varkey (Lahore, Pakistan)

Efficacy and Safety of Nicotine in Parkinson’s Disease: A Systematic Review and Meta-analysis

O. Razouk, A. Ahmad, K. Mustafa, A. Habib, A. Al Midani (Sharjah, United Arab Emirates)

Efficacy of LSVT-BIG Treatment Compared to Other Physiotherapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

A. Amin, M. Helal, A. Alsokery, H. Sabet, A. Ibrahim, A. Suleiman, I. Yakout, A. Abunamoos, M. Elsayed (Cairo, Egypt)

Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States

N. Crouse, C. Happel, M. Grall (Rockville, USA)

European Experience with Long-term Continuous Subcutaneous Apomorphine Infusions at Higher Doses

M. Grall, J. Parsons, A. de Groot, A. Sesar, P. Qin, M. Vérin (Rockville, USA)

Evaluation of Neuroprotective Effect of Terminalia macroptera on Rotenone Induced Parkinson’s Disease in Mice

L. Ior, E. Ishaya, P. Ezeuduji (Jos, Nigeria)

Fecal Microbiota Transplantation for Parkinson’s Disease: A Systematic Review and Meta-Analysis

A. Menegaz Ms, J. Martinez-Lemus Md, í. Barros Andrade, F. Tamashiro Ms, F. Westphal Filho, P. Moss Ms, J. Patiño Md, M. Schiess Md (Houston, USA)

Functional Activity of Apomorphine Relative to Dopamine at Dopamine Receptors: Findings from G Protein Coupled Receptor Biosensor Assays

B. Yegla, P. Jenner, M. Grall, J. Rubin (Rockville, USA)

Gastrointestinal Dysfunction and Levodopa Therapeutic Response in Parkinson’s Disease: A Brazilian Cross-sectional Study

N. Dos Santos, G. de Vasconcelos, G. Piñeiro, F. Brito, J. Oliveira, S. Baran, J. Costa, E. Muricy, R. Kauark (Salvador, Brazil)

Glucagon Like Peptide-1 (GLP-1) Receptor Agonists for Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis

F. Alnajjar, A. Abunamoos, M. Mustafa, Y. Aljazi, K. Moghib, A. Rababah, M. Alghaniem (Amman, Jordan)

Identifying the Prognostic Outcomes of Parkinson’s Patients with Impaired Swallow.

J. Acharya, J. Dols, A. Lingeswaran, A. Aranda-Martinez, A. Manzoor, K. Yeong, C. Chikusu, P. Enwere, R. Lisk, K. Soliman, R. Williams, E. Wilkinson (Chertsey, United Kingdom)

Impact of Over-the-counter Cannabidiol Products on Cognition During the Course of Parkinson’s Disease

A. López Lobato, D. Náfate Wences, A. Hernández Medrano, A. Cervantes Arriaga, M. Rodriguez Violante (Mexico, Mexico)

Influence of age at onset on medication profile in patients with Parkinson’s disease: A prospective study from a tertiary care center in India

VV. Holla, S. Prasad, T. Nagaraj, SGS. Bhat, M. Bhardwaj, DK. Samartha, SS. Nair, P. Mailankody, RR. Mahale, N. Kamble, R. Yadav, PK. Pal (Bengaluru, India)

Inpatient Multimodal Care Improves Parkinsonian Symptoms Regardless Of Race Or Ethnicity

N. Elayan, L. Rubin, M. Mccrossin, A. Di Rocco, M. Ghilardi (New York, USA)

Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures

N. Elayan, L. Rubin, M. Mccrossin, C. Roberts, H. Shakil, A. Di Rocco, M. Ghilardi (Long Island, USA)

Intravenous L-dopa Administration in PD and DLB Patients with Oral Intake Difficulties: Current Status and Challenges

S. Nishida (Tokai, Japan)

Investigating the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In Vitro Models

SEO. Seo, FAZ. Dustov (Tashkent, Uzbekistan)

Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson’s Disease

N. Ito, J. Ozawa, K. Kataoka, K. Matsuoka, T. Nakanishi, T. Wada, A. Ishida, M. Kanemoto, T. Oguchi, M. Tsuji, Y. Kiuchi, H. Murakami (Tokyo, Japan)

Istradefylline for Freezing of Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis

A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion

R. Serpa, K. Palsa, E. Tufano, T. Helmuth, S. Mills-Huffnagle, M. Kant, J. Connor (Hershey, USA)

Mechanistic Insights of Tamarindus indica in Acrylonitrile-Induced Neurodegeneration

L. Usman, E. Ajani, A. Akinmoladun, R. Ibrahim, R. Aladodo (Ilorin, Nigeria)

Medication Error Reduction Strategies in an In-patient Multimodal Intensive Neurorehabilitation and Care (i-MINC) Program

N. Yousefzadeh, L. Hom, A. Defrank, M. Mccrossin, L. Rubin (Glen Cove, USA)

Medication therapy in Parkinson’s disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam

T. Dang, T. Tran (HO CHI MINH, Viet Nam)

Mitigating Risk and Expanding Movement Disorder Specialist Capacity: Advancing Parkinson’s Disease Management with Integrated Monitoring, Targeted Triage and Improved Patient-Clinician Communication in Parkinson’s Disease.

A. Arnold, T. Jansen, A. Hare, S. Shaffer, S. Khandhar, R. Gilron (San Francsico, USA)

Modeling Levodopa Resistance in Parkinson’s Disease: A Novel Approach Targeting Locus Coeruleus Degeneration

A. Goel, R. Goel (Bathinda, India)

Modification of Parkinson’s Disease Сourse Using Cell Technologies

V. Chyzhyk, V. Ponomarev, A. Boika (Minsk, Belarus)

Mortality and Institutionalisation Following de Novo Use of Rotigotine Patches in Hospitalised Patients with Parkinson’s Disease

E. Kaye, K. Millington, R. Skelly (Nottingham, United Kingdom)

Motor Fluctuations in Parkinsons Disease and their Correction

M. Ganieva (Dushanbe, Tajikistan)

Mucuna pruriens for FOG in Parkinson’s disease, Do we have a solution for this trivial problem?

M. Matta, N. Sawal, S. Singh, K. Verma, S. Sharma (Chandigarh, India)

Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers

M. Minar, I. Straka, Z. Andre, M. Grofik, J. Necpal, M. Rusinkova, V. Han, Z. Kosutzka (Bratislava, Slovakia)

Natural compound Protects Dopaminergic Neurons by Targeting Oxidative Stress and Cell Death Pathways in Parkinson’s Disease

S. Pandey, R. Singh (Lucknow, India)

Neuroprotection on the Horizon: Are GLP-1 Receptor Agonists the Next Breakthrough in Parkinson’s Disease?

M. Helal, H. Aboushawareb, O. Hussein Abbas, R. Haddad, Y. Zain, A. S.A Osman, N. Hamam, A. Hassan (Zagazig, Egypt)

Novel C-KIT/C-Abl Inhibitor BK40196 Alleviates Neurodegenerative Pathology And Improves Behavioral Performance In A53T Mice

X. Liu, M. Hebron, M. Stevenson, C. Moussa (Washington, USA)

Opicapone for OFF Motor Fluctuations in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials

A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson’s disease

R. de Fiores, I. Martino, A. Quattrone, B. Vescio, G. Arabia, A. Gambardella, M. Morelli (Catanzaro, Italy)

Organoid-Based AI Clinical Trial Platform for Phase 0 Studies in Parkinson’s Disease

M. Choi, D. Kim (Daejoen, Republic of Korea)

Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis

N. Smith, B. Amlani (Reading, United Kingdom)

Pharmacological PGC-1α Activation Mitigates Dopaminergic Degeneration in Parkinson’s Disease Via Regulating Mitochondrial Homeostasis

J. Kaur, S. Naqvi (Lucknow, India)

Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion

R. Hauser, A. Videnovic, P. Odin, K. Chaudhuri, M. Shah, J. Homola, L. Bergmann, R. Gupta, O. Vaou (Tampa, USA)

Relationship Between Improvement in “On” Time, Nonmotor Symptoms, and Quality of Life in Adults Treated With Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease

K. Chaudhuri, P. Odin, J. Aldred, L. Bergmann, J. Homola, R. Gupta, A. Antonini, M. Soileau (Spokane, USA)

Repetitive Transcranial Magnetic Stimulation For Freezing Of Gait And Motor Function In Parkinson’s Disease: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

Risk factors for central nervous system side effects of amantadine

M. Nagai, N. Miyaue, Y. Ito, Y. Yamanishi, R. Ando, Y. Ihara (Ehime, Japan)

Safety Profile of Opicapone in Elderly and Very Elderly Population

D. Lopes, I. Peixoto, D. Martins, H. Brigas, H. Gama, J. Holenz (Coronado, Portugal)

Safinamide as an Adjunct Therapy for Motor Symptoms and ON-Time Extension in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

Sustained Motor Symptom Efficacy With Long-Term Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Treatment – Data From The ELEGANCE Interim Analysis

B. Amlani, N. Smith (Reading, United Kingdom)

The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease

I. Malaty, P. Odin, D. Kern, L. Bergmann, M. Shah, R. Gupta, A. Antonini, K. Chaudhuri (Gainesvile, USA)

The Effectiveness of Rivastigmine in Parkinson’s Disease: Impact on Motor Symptoms, Gait, Cognitive Function, and Falls – A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

The Impact of Levodopa on Gait in Parkinson’s Disease: A Quantitative Analysis of Striatal Dopamine Transporter Availability and Lateralization

YS. Kim, DG. Park, JH. Yoon (Suwon, Republic of Korea)

The Impact of Statin Therapy on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Meta-Analysis

V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

The neuroprotective effects of Echinacoside on α-synuclein fibril-induced Parkinson’s disease mice model

Q. Zhao, S. Bu, Z. Wang, L. Jin (Shanghai, China)

Therapeutic Effect and Mechanism of Targeted Nano-selenium in Mouse Model of Parkinson’s Disease Induced by MPTP

W. Bi, L. Zhu, T. Chen, Y. Cen, J. Zou, Z. Su (Guangzhou, China)

Therapeutic Potential of GLP-1 Receptor Agonists in Parkinson’s Disease: A Systematic Review and Meta-Analysis

A. Badran, M. Gbreel (Cairo, Egypt)

Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease

J. Szász, V. Constantin, K. Orbán-Kis, S. Bataga, R. Neagoe, M. Ciorba, K. Kelemen, I. Mihály, S. Szatmári (TARGU MURES, Romania)

Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis

N. Smith, B. Amlani (Reading, United Kingdom)

Transcranial Direct Current Stimulation (tDCS) to Enhance Cognitive Function in Parkinson’s Disease: A Systematic Review and Meta-analysis with Implications for African Healthcare

O. Uwishema (Kigali, Rwanda)

Transcutaneous Vagus Nerve Stimulation for Gait and Motor Function in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

Treatment Of Advanced Parkinson’s With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia

B. Amlani, N. Smith (Reading, United Kingdom)

Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson’s Disease

D. Rinaldi, E. Bianchini, S. Galli, G. Imbalzano, CA. Artusi (Rome, Italy)

Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication

T. Denne (Mission Viejo, USA)

Trihexyphenidyl as a Treatment for Severe Freezing of Gait in Parkinson’s Disease: A Case Report

J. Ha, M. Ferris (Palo Alto, USA)

Unraveling the Intertwined Relationship of DBS, Parkinson’s Disease Subtype and LEDD: A Retrospective Study

T. Mehta, V. Lavu, C. Hess, A. Ramirez-Zamora, M. Okun, J. Wong (Gainesville, USA)

Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors

L. Saadatpour, H. Chaparro-Solano, J. Yu, C. Sonneborn, C. Piccinin, S. Anis, E. Assaedi, P. Coss, S. Horn, O. Vaou, I. Mata, H. Fernandez (San Antonio, USA)

Updated Meta-analysis Assessing GLP-1 Agonists for Parkinson’s Disease

M. Messak, A. Abdelmageed, Y. Khattab (Helwan, Egypt)

VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease

M. Facheris, D. Ysselstein, J. van Dervalk, E. Thijssen, L. Pagan, G. Valstar, C. Schotborgh, P. Kremer, M. Hagey, J. Cederbaum, J. Sullivan, K. Hunt, O. Siddiqui (Chicago, USA)

Zonisamide for Motor Symptoms and OFF-Time Reduction in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)